Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 12/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 12/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | P4HB | P07237 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563636 | 0.75 | CYP1A1 (0.61) | CYP1A1CYP1B1MAOBP4HBCES2 | |
| SCHEMBL3563640 | 0.75 | CYP1A1 (0.61) | CYP1A1CYP1B1MAOBP4HBCES2 | |
| SCHEMBL11092190 | 0.75 | CYP1A1 (0.65) | CYP1A1CYP1B1MAOBP4HBCES2 | |
| SCHEMBL11092186 | 0.75 | CYP1A1 (0.65) | CYP1A1CYP1B1MAOBP4HBCES2 | |
| SCHEMBL710589 | 0.75 | NR4A1 (0.49) | CYP1A1CYP1B1MAOBP4HBCES2 | |
| SCHEMBL325285 | 0.71 | ALDH1A1 (0.68) | CYP1A1CYP1B1MAOBP4HB | |
| SCHEMBL325284 | 0.71 | ALDH1A1 (0.68) | CYP1A1CYP1B1MAOBP4HB | |
| SCHEMBL29275425 | 0.71 | CYP1A1 (0.56) | CYP1A1CYP1B1MAOBP4HBCES2 | |
| SCHEMBL7228800 | 0.71 | CES2 (0.59) | CYP1A1CYP1B1MAOBP4HBCES2 | |
| SCHEMBL8534398 | 0.71 | GSK3B (0.66) | CYP1A1CYP1B1CES2CES1NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | CETP, MTTP, HDLBP | CYP1A1 3434/4885CYP1B1 3553/4885MAOB 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.